Enhancer Detail

Comprehensive information about experimentally validated enhancers

About Enhancer
Enhancer ID: E_02883
Species: Homo sapiens
Position : chr1:204518514-204561889
Year: 2016
Title: Chromatin interactions and candidate genes at ten prostate cancer risk loci.
Genome Build: hg19
Enhancer Type: Enhancer
Condition: Normal
PMID:  26979803
Tissue: prostate gland
Tissue Ontology ID: UBERON:0002367
Cell Source: RWPE-1
CVCL ID: CVCL_3791
Experiment Type: Chromatin interaction assay; TF binding assay; Gene expression assay
High Throughput Method: Capture 3C-seq; ChIP-seq; RNA-seq; SNP genotyping array; 3C; eQTL analysis
Low Throughput Method: 3C-qPCR; RT-qPCR
About Target Gene
Target gene : NA
About TF
TF name : AR
About Regulatory State
Regulatory State : Active
Upstream Pathway Annotation of TF
GeneName Pathway Name Source Gene Number
AR Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 reactome 65
AR Alpha6Beta4Integrin netpath 74
AR AndrogenReceptor netpath 167
AR Coregulation of Androgen receptor activity pid 61
AR FOXA1 transcription factor network pid 45
AR IL6 netpath 85
AR Nongenotropic Androgen signaling pid 31
AR Notch-mediated HES/HEY network pid 48
AR Nuclear Receptor transcription pathway reactome 51
AR Regulation of Androgen receptor activity pid 54
AR Regulation of nuclear beta catenin signaling and target gene transcription pid 80
AR Regulation of nuclear SMAD2/3 signaling pid 82
AR TGF_beta_Receptor netpath 220
AR Oocyte meiosis kegg 110
AR Pathways in cancer kegg 321
AR Prostate cancer kegg 85
AR Hs_DNA_Damage_Response_WP707_82937 wikipathways 28
AR Hs_miRNA_Regulation_of_DNA_Damage_Response_WP1530_84694 wikipathways 28
AR Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122
AR Hs_Sudden_Infant_Death_Syndrome_(SIDS)_Susceptibility_Pathways_WP706_86078 wikipathways 33
AR Hs_Androgen_receptor_signaling_pathway_WP138_79958 wikipathways 27
Enhancer Associated Network
Overlapping Enhancers (hg19) 15 found
Enhancer ID Position Tissue Cell Disease
E_02834 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02835 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02836 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02837 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02838 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02839 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02840 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02841 chr1:204518514-204561889 prostate gland malignant cell prostate cancer
E_02866 chr1:204518514-204561889 prostate gland prostate epithelial cell NA
E_02867 chr1:204518514-204561889 prostate gland prostate epithelial cell NA
E_02868 chr1:204518514-204561889 prostate gland prostate epithelial cell NA
E_02869 chr1:204518514-204561889 prostate gland prostate epithelial cell NA
E_02884 chr1:204518514-204561889 prostate gland NA NA
E_02885 chr1:204518514-204561889 prostate gland NA NA
E_02886 chr1:204518514-204561889 prostate gland NA NA
Expression of Target Genes for the Enhancer